Should Onglyza, Zemiglo and Nesian be happy or sad on the decision?

The second type diabetes treatments of the DPP-4 inhibitor type,‘Onglyza’(generic name: saxagliptin), ‘Zemiglo’ (generic name: gemigliptin) and‘Nesian’ (generic name: alogliptin), have stuck in a ambiguous situation.

Although the criteria of the National Health Insurance benefits on DPP-4 inhibitors have been extended, the products were excluded from the target range due to their low market sh...